1. GPCR/G Protein
  2. GCGR
  3. Dulaglutide

Dulaglutide (LY2189265) is a glucagon-like peptide-1 (GLP-1) receptor agonist. Dulaglutide can be uesd for the research of type 2 diabetes (T2D) .

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Kundenspezifische Peptidsynthese

CAS. Nr. : 923950-08-7

Größe Preis Verfügbarkeit Menge
1 mg Auf Lager
5 mg Auf Lager
10 mg Auf Lager
25 mg Auf Lager
50 mg Auf Lager
100 mg   Angebot einholen  
200 mg   Angebot einholen  

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

This product is a controlled substance and not for sale in your territory.

Kundenbewertung

Based on 1 publication(s) in Google Scholar

Other Forms of Dulaglutide:

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Dulaglutide

Cell Imaging/Staining
RT-PCR
WB
Others

    Dulaglutide purchased from MedChemExpress. Usage Cited in: Endocrinol Metab. 2022 Feb;37(1):74-83.  [Abstract]

    Dulaglutide (Dula) inhibits palmitic acid (PA)-induced lipid accumulation in HepG2 cells. Cells were pre-treated with 400 μM PA for 24 hours, followed by treatment with or without 100 nM Dula for 24 hours. Lipid accumulation were evaluated using Oil red O staining.

    Dulaglutide purchased from MedChemExpress. Usage Cited in: Endocrinol Metab. 2022 Feb;37(1):74-83.  [Abstract]

    Dula glycopeptide (Dula) reduced lipogenesis and triglyceride (TG) synthesis in palmitic acid (PA)-treated HepG2 cells and increased TG secretion. HepG2 cells were pretreated with 400 μM PA for 24 hours, followed by treatment with or without 100 nM Dula for 24 hours. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to analyze the mRNA expression levels of genes encoding sterol regulatory binding protein 1 (SREBP-1), acetyl-CoA carboxylase (ACC), and fatty acid synthase (FAS).

    Dulaglutide purchased from MedChemExpress. Usage Cited in: Endocrinol Metab. 2022 Feb;37(1):74-83.  [Abstract]

    Cells were pre-treated with 400 μM PA for 24 hours, followed by treatment with or without 100 nM Dulaglutide and 100 nM exendin (9–39), a GLP-1R antagonist, for 24 hours. FAM3A, GLP-1R, sirtuin 1 (SIRT1), phospho-adenosine monophosphate-activated protein kinase (p-AMPK), phospho-acetyl-CoA carboxylase (p-ACC), and peroxisome proliferator-activated receptor alpha (PPARα) levels were analyzed using Western blotting.

    Dulaglutide purchased from MedChemExpress. Usage Cited in: Endocrinol Metab. 2022 Feb;37(1):74-83.  [Abstract]

    Dulaglutide (Dula) inhibits lipid deposition and increases fatty acid oxidation via family with sequence similarity 3 member A (FAM3A). HepG2 cells transfected with 10 nM FAM3A small interfering RNA (siRNA) or control (Con) siRNA for 24 hours were pretreated with 400 μM palmitic acid (PA) for 24 hours, followed by treatment with or without 100 nM Dula for 24 hours. Lipid deposition was evaluated using triglyceride (TG) content assay.
    • Biologische Aktivität

    • Reinheit & Dokumentation

    • Verweise

    • Kundenbewertung

    Beschreibung

    Dulaglutide (LY2189265) is a glucagon-like peptide-1 (GLP-1) receptor agonist. Dulaglutide can be uesd for the research of type 2 diabetes (T2D) [1][2].

    IC50 & Target

    GLP-1 receptor[1]

    In Vitro

    Dulaglutide (50 nM and 100 nM; 24 h) ameliorates ox-LDL-induced oxidative stress and suppresses ox-LDL-induced mitochondrial dysfunction in human aortic endothelial cells (HAECs)[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Viability Assay[1]

    Cell Line: Human aortic endothelial cells (HAECs)
    Concentration: 50 nM, 100 nM
    Incubation Time: 24 hous
    Result: Suppressed ox-LDL-induced reduction of cell viability and release of lactate dehydrogenase (LDH).
    In Vivo

    Dulaglutide (0, 0.05, 0.5, 1.5, or 5 mg/kg; s.c.; twice week, for 93 weeks) increases the incidence of thyroid C-cell hyperplasia and neoplasia in the rat carcinogenicity study[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Rats and Transgenic mice[1]
    Dosage: 0, 0.05, 0.5, 1.5, or 5 mg/kg; 0, 0.3, 1, or 3 mg/kg
    Administration: SC, twice week, for 93 weeks; SC, twice week, for 26 weeks
    Result: Statistically increased diffuse C-cell hyperplasia and adenomas at >0.5 mg/kg.
    Decreased Systemic exposures over time in mice.
    Klinische Studie
    Molekulargewicht

    62561 (Glycosylation, Dominant form)

    CAS. Nr.
    Appearance

    Liquid

    Color

    Colorless to light yellow

    Versand

    Room temperature in continental US; may vary elsewhere.

    Speicherung

    Store at 4°C, do not freeze

    Reinheit & Dokumentation

    Purity: 96%

    Verweise
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molaritätsrechner

    • Verdünnungsrechner

    Die Formel zur Berechnung von Molaritäten

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)

    Diese Gleichung wird häufig abgekürzt als: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Ihre kürzlich angesehenen Produkte:

    Online-Anfrage

    Your information is safe with us. * Required Fields.

    Produktname

     

    Requested Quantity *

    Name des Antragstellers *

     

    Anrede

    E-Mail-Addresse *

     

    Telefonnummer *

    Department

     

    Name der Organisation *

    City

    Bundesland

    Country or Region *

         

    Bemerkungen

    Massenanfrage

    Inquiry Information

    Produktname:
    Dulaglutide
    Art. -Nr.:
    HY-P0120
    Menge:
    MCE Japan Authorized Agent: